A Abbvie
| Market Cap | $369.39B |
| P/E Ratio | 88.49 |
| Forward P/E | 12.96 |
| Dividend Yield | 3.31% |
| Beta | 0.36 |
| 52W Range | $166.16 - $240.69 |
| # Hedge Funds | 8 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Hedge Fund Ownership
| Investor 8 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Torray Funds Torray Investment Partners | 3.03% | $21.18M | 92,687 | Reduce 8.80% |
| David Katz Matrix Asset Advisors | 0.79% | $8.75M | 38,285 | Reduce 1.36% |
| FPA Queens Road Small Cap Value Fund Bragg Financial Advisors | 0.55% | $16.77M | 73,379 | Reduce 1.79% |
| Mairs & Power Growth Fund Mairs & Power Inc | 0.10% | $10.61M | 46,456 | Reduce 2.03% |
| Jensen Investment Management Jensen Investment Management | 0.04% | $2.55M | 11,144 | Reduce 38.51% |
| Thomas Russo Gardner Russo & Quinn | 0.03% | $2.83M | 12,410 | — |
| Dodge & Cox Dodge & Cox | 0.00% | $2.37M | 10,393 | Reduce 0.76% |
| Bill Nygren Harris Associates LP | 0.00% | $612.00K | 2,682 | Reduce 15.21% |
Insider Trading
| Insider Name of the company insider who made the trade 6 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Purdue David RyanSVP, Controller | Sale | 5,230 | $233.56 | $1.22M | 04 Mar 2026 | 06 Mar 2026 |
| David Ryan PurdueSVP, Controller | Sale | 5,230 | $233.56 | $1.22M | 04 Mar 2026 | 06 Mar 2026 |
| Siatis Perry CEVP, GC AND SECRETARY | Sale | 2,600 | $235.26 | $611.68K | 02 Mar 2026 | 03 Mar 2026 |
| Siatis Perry CEVP, GC AND SECRETARY | Sale | 10,291 | $234.66 | $2.41M | 02 Mar 2026 | 03 Mar 2026 |
| Siatis Perry CEVP, GC AND SECRETARY | Sale | 5,777 | $233.51 | $1.35M | 02 Mar 2026 | 03 Mar 2026 |
| Siatis Perry CEVP, GC AND SECRETARY | Sale | 22,381 | $230.00 | $5.15M | 25 Feb 2026 | 27 Feb 2026 |
Frequently Asked Questions
What is ABBV stock price today?
Abbvie (ABBV) is currently trading at $208.84. The stock has a 52-week range of $166.16 to $240.69 and a market capitalization of $369.39B.
Is ABBV a good stock to buy in 2026?
Abbvie has a P/E ratio of 88.5 (forward P/E: 13.0), a dividend yield of 3.31%, and 1-year performance of +7.0%. 8 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling ABBV stock?
There have been 6 insider transactions for ABBV in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has ABBV stock performed over the past year?
Abbvie (ABBV) has returned +7.0% over the past 12 months. The stock traded between $166.16 and $240.69 during this period, and is currently at $208.84.
Which hedge funds own ABBV (Abbvie)?
8 tracked hedge funds currently hold ABBV in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is ABBV's market cap and valuation?
Abbvie (ABBV) has a market capitalization of $369.39B. The trailing P/E ratio is 88.5 and forward P/E is 13.0. The stock is classified in the Healthcare sector.
What is ABBV's revenue and profitability?
Abbvie reported revenue of $61.16B with net income of $4.19B and a profit margin of 0.07%. The stock has a beta of 0.36.
What sector is ABBV in and who are its biggest institutional holders?
Abbvie (ABBV) operates in the Healthcare sector. It is held by 8 tracked hedge funds. See the ownership table above for the complete list.